PlainRecalls
FDA Drug Moderate Class II Ongoing

LOSARTAN POTASSIUM TABLETS, USP 25 mg, Bulk, Rx only, For Further Manufacturing, Packing or Repackaging only, Manufactured by: Arrow Pharma (Malta) Ltd., Birzebbugia Malta NDC 0591-3745-00

Reported: April 15, 2020 Initiated: March 25, 2020 #D-1100-2020

Product Description

LOSARTAN POTASSIUM TABLETS, USP 25 mg, Bulk, Rx only, For Further Manufacturing, Packing or Repackaging only, Manufactured by: Arrow Pharma (Malta) Ltd., Birzebbugia Malta NDC 0591-3745-00

Reason for Recall

CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.

Details

Recalling Firm
Teva Pharmaceuticals USA
Units Affected
N/A
Distribution
Bulk product was distributed to one re-packager in California.
Location
Parsippany, NJ

Frequently Asked Questions

What product was recalled?
LOSARTAN POTASSIUM TABLETS, USP 25 mg, Bulk, Rx only, For Further Manufacturing, Packing or Repackaging only, Manufactured by: Arrow Pharma (Malta) Ltd., Birzebbugia Malta NDC 0591-3745-00. Recalled by Teva Pharmaceuticals USA. Units affected: N/A.
Why was this product recalled?
CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.
Which agency issued this recall?
This recall was issued by the FDA Drug on April 15, 2020. Severity: Moderate. Recall number: D-1100-2020.